Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.6587
- Book/Share 2.3783
- PB 0.7695
- Debt/Equity 0.07
- CurrentRatio 4.1783
- ROIC -0.4632
- MktCap 611099220.0
- FreeCF/Share -1.0763
- PFCF -1.7586
- PE -1.5741
- Debt/Assets 0.0556
- DivYield 0
- ROE -0.4971
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
Iovance Stock Sinks 46%. Here's Why the Biotech Is Tumbling.
Published: May 09, 2025 by: Barrons
Sentiment: Negative
The oncology drug maker posts a wider-than-expected loss in the first quarter.
Read More
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Negative
IOVA's Q1'25 product revenue was $49.3M, impacted by production facility maintenance; however, Q2'25 estimates for infusions imply weak growth, despite not being impacted by production. Replimune's RP1 could be approved in July 2025, providing market competition for melanoma patients. Obsidian Therapeutics will present phase 1 data from the Agni-01 trial of their cell therapy OBX-115 at ASCO 2025 on June 2.
Read More
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Negative
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Brian Gastman - EVP, Medical Affairs Conference Call Participants Andrew Tsai - Jefferies Tyler Van Buren - TD Cowen Salim Syed - Mizuho Andrea Newkirk - Goldman Sachs Yanan Zhu - Wells Fargo Colleen Kusy - Baird Peter Lawson - Barclays Reni Benjamin - Citizens Operator Good day and thank …
Read More
My 3 Favorite Stocks to Buy Right Now
Published: May 06, 2025 by: The Motley Fool
Sentiment: Positive
Veteran investors know that the market's recent weakness is more of an opportunity than an omen. Sure, stocks may not have hit their ultimate bottom just yet.
Read More
2 Beaten-Down Stocks With Incredible Upside Potential
Published: April 30, 2025 by: The Motley Fool
Sentiment: Positive
Iovance Biotherapeutics (IOVA -1.52%) and CRISPR Therapeutics (CRSP -1.27%) are two incredibly innovative biotechs, but this hasn't translated into strong performances recently. Both stocks have significantly lagged the market over the past three years due to a combination of factors.
Read More
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
Published: March 12, 2025 by: The Motley Fool
Sentiment: Negative
When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play.
Read More
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Negative
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins.
Read More
Iovance Biotherapeutics, Inc. (IOVA) Q4 2024 Earnings Call Transcript
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO and President Dan Kirby - CCO Igor Bilinsky - COO Jean-Marc Bellemin - CFO Friedrich Graf Finckenstein - CMO Conference Call Participants Andrea Newkirk - Goldman Sachs Peter Lawson - Barclays Ben Burnett - Stifel Colleen Kusy - Baird Yanan Zhu - Wells Fargo Securities Asthika Goonewardene - Truist Reni Benjamin - Citizens JMP David Dai - UBS Andrew Tsai - Jefferies Operator Good day and thank you for …
Read More
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Negative
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago.
Read More
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M
Read More
What's in Store for These 5 Biotech Stocks This Earnings Season?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Read More
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025.
Read More
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 10, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 305,000 shares of Iovance's common stock to Daniel Kirby, the Company's new Chief Commercial Officer.
Read More
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today.
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D.
- Employees 838